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Abstract 
Radiolabeled bombesin analogs are promising probes for cancer imaging of gastrin-releasing 
peptide receptor (GRPR). In this study, we developed 
18F-labeled GRPR agonists and an-
tagonists for positron emission tomography (PET) imaging of prostate cancer. GRPR antag-
onists  ATBBN  (D-Phe-Gln-Trp-Ala-Val-Gly-His-Leu-NHCH2CH3)  and  MATBBN 
(Gly-Gly-Gly-Arg-Asp-Asn-D-Phe-Gln-Trp-Ala-Val-Gly-His-Leu-NHCH2CH3),  and  agonists 
AGBBN (Gln-Trp-Ala-Val-Gly-His-Leu-MetNH2) and MAGBBN (Gly-Gly-Gly-Arg-Asp-Asn- 
Gln-Trp-Ala-Val-Gly-His-Leu-MetNH2)  were  radiolabeled  with 
18F  via  4-nitrophenyl 
2-
18F-fluoropropionate. The in vitro receptor binding, cell uptake, and efflux properties of the 
radiotracers were studied on PC-3 cells. An in vivo PET study was performed on mice bearing 
PC-3 tumors. Direct 
18F-labeling of known GRPR antagonist ATBBN and agonist AGBBN did 
not result in good tumor targeting or appropriate pharmacokinetics. Modification was made 
by introducing a highly hydrophilic linker Gly-Gly-Gly-Arg-Asp-Asn. Higher receptor binding 
affinity,  much  higher  cell  uptake  and  slower  washout  were  observed  for  the  agonist 
18F-FP-MAGBBN  over  the  antagonist 
18F-FP-MATBBN.  Both  tracers  showed  good  tu-
mor/background contrast, with the agonist 
18F-FP-MAGBBN having significantly higher tumor 
uptake  than  the  antagonist 
18F-FP-MATBBN  (P  <  0.01).  In  conclusion, 
Gly-Gly-Gly-Arg-Asp-Asn linker significantly improved the pharmacokinetics of the otherwise 
hydrophobic BBN radiotracers. 
18F-labeled BBN peptide agonists may be the probes of choice 
for prostate cancer imaging due to their relatively high tumor uptake and retention as 
compared with the antagonist counterparts. 
Key words: gastrin-releasing peptide receptor (GRPR); bombesin (BBN); agonist; antagonist; posi-
tron emission tomography (PET); 18F 
INTRODUCTION 
Peptide-based  molecular  imaging  probes  that 
target receptors over-expressed on cancer cells have 
attracted intensive research attention due to their fast 
clearance,  excellent  tissue  penetration  and  low  im-
munogenicity [1-3]. Among various tumor targeting 
peptides,  bombesin  (BBN)  analogs  are  of  particular Theranostics 2011, 1 
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interest because BBN targets gastrin-releasing peptide 
receptor  (GRPR),  which  is  overexpressed  in  a  wide 
spectrum of human tumors, including prostate can-
cer,  breast  cancer,  small  cell  lung  cancer,  ovarian 
cancers,  endometrial  cancers,  and  gastrointestinal 
stromal tumors [4-8]. In particular, radiolabeled BBN 
analogs  [9-11]  have  been  developed  for  imaging  of 
prostate  cancer,  which  has  long  been  the  leading 
cause of cancer related death in men in the US and 
Europe.  
Positron  emission  tomography  (PET)  using  ra-
diolabeled peptides is of great interest in diagnostic 
nuclear medicine [12-13]. Compared to single-photon 
emission  computed  tomography  (SPECT),  PET  is 
more  quantitative  and  provides  better  spatial  and 
temporal  resolution.  18F  with  almost  100%  positron 
efficiency,  low  β+  energy  (0.64  MeV)  and  relatively 
short  physical  half-life  (t1/2  =  109.7  min)  is  ideally 
suited for peptide labeling and PET imaging. Despite 
many  advantages  of  PET  and  18F-labeled  molecular 
imaging  probes,  most  BBN  radiotracers  reported  to 
date  are  labeled  with  radiometals,  such  as  99mTc  or 
64Cu, for either SPECT or PET imaging [9-10]. We and 
others developed a number of 18F-labeled BBN radio-
tracers [14-17]. Unfortunately, the potential for clinical 
translation of these probes is limited due to their poor 
tumor/background  contrast  and  unfavorable  renal 
and hepatobiliary clearance.  
Recent  studies  concluded  that  radiomet-
al-labeled  GRPR  antagonists  are  remarkably  better 
than the agonists. For example, the tumor uptake in 
PC-3  tumor-bearing  mice  is  4-fold,  and  the  tu-
mor/kidney  ratio  is  7.5-fold,  for  the  99mTc-labeled 
BBN receptor antagonist at 4 h post injection as com-
pared with the corresponding  99mTc-labeled BBN re-
ceptor agonist [18]. A few other studies also focused 
on radiometal labeled GRPR antagonists [19-22]. Be-
cause the physical properties and labeling strategies 
of  non-metallic  radioisotopes,  such  as  18F,  are  quite 
different from those of radiometals, the generality of 
the conclusion that antagonists are better than ago-
nists needs to be verified for other non-metal radioi-
sotope-labeled  BBN  analogs.  For  this  purpose,  we 
developed both  18F-labeled BBN antagonists and ag-
onists  for  side-by-side  comparative  studies.  In  con-
trast to the reported radiometal-labeled BBN deriva-
tives,  our  18F-labeled  receptor  agonist  had  much 
higher  tumor  uptake  than  the  receptor  antagonist. 
Herein, we would like to report the development of 
these  radiotracers  (Fig.  1)  including  comparative  in 
vitro receptor-binding, cell uptake, and efflux studies 
on PC-3 cells and in vivo small PET imaging study of 
PC-3 tumor mice.  
 
FIGURE  1.  Structures  of 
18F-radiolabeled  bombesin  (BBN)  receptor  antagonist 
18F-FP-MATBBN  and  agonist 
18F-FP-MAGBBN.  Theranostics 2011, 1 
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MATERIALS AND METHODS 
All  chemicals  were  purchased,  of  analytical 
grade, and used as received without further purifica-
tion,  unless  otherwise  stated.  BBN  receptor  antago-
nists,  ATBBN  (D-Phe-Gln-Trp-Ala-Val-Gly- 
His-Leu-NHCH2CH3)  and  MATBBN 
(Gly-Gly-Gly-Arg-Asp-Asn-D-Phe-Gln-Trp-Ala-Val-
Gly-His-Leu-NHCH2CH3),  and  agonists  AGBBN 
(Aca-Gln-Trp-Ala-Val-Gly-His-Leu-MetNH2)  and 
MAGBBN  (Gly-Gly-Gly-Arg-Asp-Asn-Gln-Trp-Ala- 
Val-Gly-His-Leu-MetNH2) were prepared via stand-
ard  solid-phase  Fmoc  chemistry  with  an  automatic 
peptide synthesizer (CS Bio). No-carrier-added 18F-F- 
was produced from an in-house GE Healthcare PET-
trace cyclotron. C18 Sep-Pak cartridges (Waters) were 
pretreated  with  ethanol  (5  mL)  and  water  (10  mL) 
before  use.  The  syringe  filter  and  polyethersulfone 
membranes  (pore  size,  0.22  mm;  diameter,  13  mm) 
were  purchased  from  Nalge  Nunc  International. 
125I-[Tyr4]BBN (74 TBq/mmol (2,000 Ci/mmol)) was 
purchased  from  Perkin-Elmer.  Analytical  and 
semi-preparative  RP-HPLC  (reversed-phase 
high-performance liquid chromatography) were per-
formed on a Waters 600 chromatography system with 
a  Waters  996  photodiode  array  detector  and  Beck-
man170  radioisotope  detector.  A  C18  Vydac  protein 
and peptide column (218TP510; 5 μm, 250 × 10 mm) 
was used for peptide purification. The flow was set at 
5 mL/min using a gradient system starting from 95% 
solvent A (0.1% TFA [trifluoroacetic acid] in water) 
and 5% solvent B (0.1% TFA in ACN [acetonitrile]) 
(0–2 min) and ramped to 35% solvent A and 65% sol-
vent B at 32 min. The flow rate of the analytical HPLC 
was set at 1 mL/min using the same gradient system, 
but with a C18 Vydac column (218TP54, 5 μm, 250 × 
4.6 mm). The ultraviolet (UV) absorbance was moni-
tored at 218 nm and the identification of the peptides 
was confirmed based on the UV spectrum acquired 
using  a  photodiode  array  detector  and  mass  spec-
trometry. 
Synthesis of FP-BBN Peptide Conjugates 
Representative  procedure:  O-(N-succinimidyl)- 
1,1,3,3-tetramethyluronium  tetrafluoroborate  (TSTU, 
13.7 μmol) and DIPEA (20 μL) were added to a solu-
tion  of  2-fluoropropionic  acid  (FPA,  13.7  μmol)  in 
DMF (200 μL). The mixture was heated at 60ºC for 30 
min and the BBN peptide (13.7 μmol) was added. Af-
ter 30 min, the reaction mixture was quenched with 2 
mL of 5% HOAc. The crude FP-BBN peptide conju-
gate  was  purified  by  semi-preparative  HPLC.  The 
desired  fractions  were  collected  and  lyophilized  to 
give  a  white  powder  in  >85%  yield.  The  product 
identity  and  purity  were  confirmed  by  mass  spec-
trometry (ESI-MS) and analytical HPLC: (FP-ATBBN, 
m/z  1058.58  for  [MH]+  (C52H73FN13O10,  calculated 
molecular weight [MW] 1058.21, HPLC retention time 
23.4  min);  FP-MATBBN,  m/z  1614.91  for  [MH]+ 
(C72H105FN23O19,  calculated  molecular  weight  [MW] 
1614.79,  HPLC  retention  time  19.4  min); 
FP-MAGBBN,  m/z  1571.14  for  [MH]+ 
(C66H101FN23O19S, calculated molecular weight [MW] 
1570.71), HPLC retention time 17.2 min). 
Radiochemistry 
Representative  procedure:  4-nitrophenyl 
2-18F-fluoropropionate  (18F-NFP)  was  prepared  ac-
cording  to  a  previously  reported  procedure  [23-24]. 
BBN peptide (500 μg) solution in DMSO (200 μL) was 
added to dried  18F-NFP in a 5 mL reaction vial, fol-
lowed by the addition of DIPEA (20 μL). The reaction 
mixture was heated for 15 min at 40 ºC and was then 
quenched  with  800  μL  of  5%  HOAc.  The  crude 
18F-labeled peptide was purified by semi-preparative 
HPLC. The  desired  fractions  were  collected  and  di-
luted with 15 mL of water. The dilution was passed 
through a C18 cartridge, and the cartridge was washed 
with 5 mL of water. The purified 18F-labeled peptide 
was  eluted  with  1  mL  of  ethanol.  The  elution  was 
blown  dry  with  a  stream  of  nitrogen  at  40ºC.  The 
dried product was formulated in normal saline and 
passed through a 0.22-μm Millipore filter into a sterile 
multidose vial for in vitro and in vivo experiments. The 
radiochemical yields from18F-NFP were 36.1 ± 2.8% (n 
= 3), 90.4 ± 4.6% (n = 3) and 78.0 ± 8.0% (n = 3) for 
18F-FP-ATBBN,  18F-FP-MATBBN  and 
18F-FP-MAGBBN, respectively. 
Cell Lines and Animal Models  
A PC-3 human prostate carcinoma cell line pur-
chased  from  American  Type  Culture  Collection 
(ATCC) was used for in vitro study and preparation of 
animal models. PC-3 cells were grown in F-12K nu-
trient  mixture  (Kaighn’s  modification)  (Invitrogen) 
which was supplemented with 10% (v/v) fetal bovine 
serum  (Invitrogen)  at  37ºC  with  5%  CO2.  Animal 
procedures were performed according to a protocol 
approved by the Institutional Animal Care and Use 
Committee of the Clinical Center, National Institutes 
of  Health.  Subcutaneous  injection  of  5  ×  106  tumor 
cells into the front flank of male athymic nude mice 
(Harlan) generated the PC-3 tumor model. When the 
tumor volume reached 100–300 mm3 (3–4 weeks after 
inoculation), the  mice  underwent small animal PET 
studies.  Theranostics 2011, 1 
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In Vitro Cell Binding Assay 
The in vitro GRPR binding affinity of FPA-BBN 
peptide  conjugates  was  measured  via  displacement 
cell-binding  assays  using  125I-[Tyr4]BBN  as  the  radi-
oligand.  Experiments  were  performed  on 
GRPR-expressing  PC-3  human  prostate  carcinoma 
cells  following  a  previously  described  method  [25]. 
IC50 (the best-fit 50% inhibitory concentration) values 
were determined using GraphPad Prism 4 (GraphPad 
Software, Inc.) by fitting the data with nonlinear re-
gression. Experiments were performed with triplicate 
samples.  
Intracellular Calcium Mobilization 
To ensure that the BBN analogs maintained their 
original  agonist  or  antagonist  characteristics  after 
modification and 18F-labeling, an intracellular calcium 
mobilization study was conducted. Intracellular cal-
cium mobilization was measured in PC-3 cells using 
Fluorometric Imaging Plate Reader (FLIPR) Calcium 
Assay  Kits  (Molecular  Devices)  according  to  the 
manufacturer’s  protocol.  In  brief,  PC-3  cells  (30,000 
cells  per  well)  were  seeded  in  96-well  Costar  black 
clear bottom plates (Corning) and cultured for 1 d at 
37°C in a humidified atmosphere containing 5% CO2. 
After  removal  of  the  growth  medium,  cells  were 
loaded with 30 μL per well FLIPRTETRA® dye con-
taining 2.5 mM probenecid for 60 min at 37°C and 5% 
CO2.  Changes  in  intracellular  Ca2+  were  monitored 
using  FLIPR  after  different  concentrations  of  BBN 
derivatives were added. The IC50 values were deter-
mined using GraphPad Prism 4 (GraphPad Software, 
Inc.)  by  fitting  the  data  with  nonlinear  regression. 
Experiments were performed with triplicate samples.  
Cell Uptake and Washout Studies 
Cell uptake and washout studies of  18F-labeled 
BBN antagonists and agonists were performed with 
PC-3 cells. In the cell uptake experiment, PC-3 cells 
were seeded into 24-well plates at a density of 1 × 105 
cells per well for overnight incubation. After incuba-
tion,  PC-3  cells  were  washed  3  times  with  PBS 
(phosphate buffered saline) and then 18F-labeled BBN 
peptide  was  added  in  triplicate  (~0.5  μCi/well). 
Re-incubation was followed at 37 °C. At 15, 30, 60, and 
120 min time points, the PC-3 cells were rinsed 3 times 
with PBS and lysed with 0.1 M NaOH. The cell lysate 
was  collected  and  the  remaining  radioactivity  was 
measured in a γ counter (Packard, Meriden, CT). In 
the washout experiment, PC-3 cells were seeded into 
24-well plates at a density of 1 × 105 cells per well be-
fore overnight incubation. After incubation, the PC-3 
cells  were  rinsed  3  times  with  PBS  and  then 
18F-labeled BBN peptide was added in triplicate (~0.5 
μCi/well). After 2 h incubation at 37 ºC, the cells were 
washed  with  PBS,  and  then  re-incubated  in  se-
rum-free medium. At 0, 15, 30, 60 and 120 min, the 
cells  were  washed  with  PBS  and  lysed  with  0.1  M 
NaOH. The cell lysate was collected and the remain-
ing  radioactivity  was  measured  with  a  γ  counter 
(Packard, Meriden, CT). The cell uptake and washout 
values were normalized in terms of added radioac-
tivity and expressed as the percent added radioactiv-
ity.  All  experiments  were  performed  with  triplicate 
wells. 
Small Animal PET Studies 
Small animal PET scans and image data analysis 
were performed using an Inveon microPET (Siemens 
Medical Solutions). Mice bearing PC-3 tumors were 
injected  under  isoflurane  anesthesia  with  ~3.7  MBq 
(100  μCi)  of  18F-labeled  BBN  receptor  antagonist  or 
agonist via  tail vein. Five-minute static PET images 
were acquired at 30 min, 1 h, and 2 h postinjection. 
The  image  reconstruction  was  done  by  the 
2-dimensional ordered subsets expectation maximum 
(OSEM) algorithm without attenuation or scatter cor-
rection.  For  GRPR  receptor-blocking  experiment, 
[Lys3]BBN (15 mg/kg) was co-injected with 3.7 MBq 
of 18F-labeled BBN peptide into PC-3 tumor mice. The 
5-min static microPET scans were acquired at 1 h post 
injection. Regions of interest (ROIs) over the tumor, 
normal tissue, and major organs were drawn on de-
cay-corrected  whole-body  coronal  images  using 
vendor software (ASI Pro 5.2.4.0) for each microPET 
scan. The radioactivity concentration (accumulation) 
within a tumor or an organ was obtained from mean 
pixel values within the multiple ROI volume, which 
had  been  converted  to  MBq/mL/min  by  using  a 
conversion  factor.  The  conversion  to  MBq/g/  min 
assumed  a  tissue  density  of  1  g/mL.  Imaging 
ROI-derived % ID/g was calculated by dividing the 
ROIs by the administered activity.  
Statistical Analysis 
Quantitative data are expressed as mean ± SD. 
Means were compared using 1-way ANOVA and the 
Student’s t test. P values of < 0.05 were considered 
statistically significant.  
RESULTS 
Chemistry and Radiochemistry  
Solid-phase peptide syntheses of BBN receptor 
antagonists  ATBBN  (D-Phe-Gln-Trp-Ala-Val-Gly- 
His-Leu-NHCH2CH3)  and  MATBBN 
(Gly-Gly-Gly-Arg-Asp-Asn-D-Phe-Gln-Trp-Ala-Val-
Gly-His-Leu-NHCH2CH3),  and  agonists  AGBBN 
(Aca-Gln-Trp-Ala-Val-Gly-His-Leu-MetNH2)  and Theranostics 2011, 1 
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MAGBBN  (Gly-Gly-Gly-Arg-Asp-Asn-Gln-Trp- 
Ala-Val-Gly-His-Leu-MetNH2) were performed using 
standard  Fmoc  chemistry.  The  FPA-peptide  conju-
gates  were  synthesized  by  reacting  TSTU  activated 
2-fluoropropionic  acid  with  corresponding  peptides 
in  70-95%  yields.  The  resulting  FPA-antagonist  or 
FPA-agonist conjugates were purified by RP-HPLC. 
The purity and identity of products were confirmed 
by HPLC and ESI mass spectrometry. The 18F radio-
labeling  was  conducted  using  previously  described 
methods  [26].  The  radiolabeling  yield  was  around 
30% from  18F-NPF for unmodified ATBBN and 90% 
for  MATBBN.  The  main  reason  that  18F-labeling  of 
Gly-Gly-Gly-Arg-Asp-Asn  linker-modified  peptides 
gave higher radiolabeling yields than the unmodified 
peptides was that acylation of 18F-NPF with the amino 
group of phenylalanine in ATBBN encountered high 
steric hindrance, while the N-terminal glycine amine 
group in MATBBN was very reactive towards acyla-
tion. High chemical and radiochemical purity (>95%) 
were observed for all radiotracers. The specific activi-
ties at the end of synthesis were determined to be 40.5 
± 3.9 TBq/mmol, 58.2 ± 7.3 TBq/mmol and 48.3 ± 4.0 
TBq/mmol for  18F-FP-ATBBN,  18F-FP-MATBBN and 
18F-FP-MAGBBN, respectively. 
Cell Binding Assay 
The  binding  affinities  of  BBN  derivatives  to 
GRPR were evaluated using 125I-[Tyr4]BBN as the ra-
dioligand in GRPR-positive PC-3 cells. Results of the 
cell-binding  assay  were  plotted  as  sigmoid  curves 
showing the displacement of 125I-[Tyr4]BBN from PC-3 
cells as a function of increasing concentration of the 
BBN analogs. The IC50 values were determined to be 
16.4, 65.3, 55.7, 94.3, 46.7 and 55.9 nM on PC-3 cells for 
ATBBN,  MATBBN,  FP-ATBBN,  FP-MATBBN, 
MAGBBN  and  FP-MAGBBN,  respectively  (Fig.  2). 
Modification of the original peptide sequences with 
Gly-Gly-Gly-Arg-Asp-Asn  linker  and  conjugation 
with FPA somewhat decreased the binding affinity of 
peptide analogs to GRPR.  
Intracellular Calcium Mobilization 
The compounds were evaluated for their effect 
on signaling by using a calcium mobilization assay in 
PC-3  cells.  As  seen  in  Figure  3,  MAGBBN  and 
FP-MAGBBN  stimulated  calcium  mobilization  and 
behaved as receptor agonists with IC50 values of 0.18 
and  0.17  µM,  respectively.  ATBBN,  MATBBN  and 
FP-MATBBN behaved as receptor antagonists with-
out  stimulating  calcium  mobilization.  These  results 
indicated that modification and  18F-labeling did not 
change the agonistic or antagonistic characteristics of 
the BBN analogs.  
 
FIGURE 2. Cell binding assay of BBN receptor antagonists 
and  agonists  (n  =  3).  Inhibition  of 
125I-[Tyr
4]BBN 
(GRPR-specific) binding to GRPR on PC-3 cells by BBN 
receptor  antagonists  ATBBN,  FP-ATBBN,  MATBBN, 
FP-MATBBN (A) and agonists MAGBN and FP-MAGBBN 
(B). 
 
 
FIGURE 3. Intracellular calcium mobilization of ATBBN, 
MATBBN, FP-MATBBN, MAGBBN and FP-MAGBBN (n = 
3). 
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Cell Uptake Studies 
The  cell  uptake  of  18F-FP-MATBBN  and 
18FP-MAGBBN  was  evaluated  in  GRPR-expressing 
PC-3  tumor  cells.  Figure  4A  shows  the  cell  uptake 
results at 4 °C and 37 °C. All tracers had rapid binding 
to the cells. The uptake reached maximum at around 
15 min and plateaued after a decrease. For BBN re-
ceptor agonist 18F-FP-MAGBBN, the cell uptake value 
at 37 °C was 2-fold higher than that at 4 °C (P < 0.01), 
suggesting  that  receptor-mediated  internalization 
occurred  at  higher  temperature.  For  BBN  receptor 
antagonist 18F-FP-MATBBN, the cell uptake at differ-
ent temperatures (4 °C and 37 °C) showed no signifi-
cant difference (P > 0.05), which was consistent with 
previous reports that receptor antagonists do not in-
ternalize into cells. The PC-3 cell uptake peak values 
(at 37 °C, 15 min post-injection) of  18F-FP-MAGBBN 
agonist  and  18F-FP-MATBBN  antagonist  were  1.2  ± 
0.07% and 0.3 ± 0.07% (n = 3, mean ± SD), respectively 
(P  <  0.01).  The  cell  uptake  values  of  BBN  receptor 
agonist  were  significantly  higher  than  those  of  an-
tagonist,  likely  due  to  the  receptor-mediated  inter-
nalization of the agonists into PC-3 cells.  
 
FIGURE 4. Cell uptake and washout assays of BBN re-
ceptor  antagonists  and  agonists.  (A)  PC-3  cell  uptake 
18F-FP-MATBBN and 
18F-FP-MAGBBN on PC-3 cells at 4°C 
and  37°C.  (B)  Loss  of 
18F-FP-MATBBN  and 
18F-FP-MAGBBN from PC-3 cells at 37°C. (n = 3, mean ± 
SD).  
 
Much faster washout rate was observed for the 
BBN receptor antagonist  18F-FP-MATBBN compared 
to that of the agonist  18F-FP-MAGBBN when the la-
beled  cells  were  incubated  in  serum-free  medium 
devoid of radioactivity (Fig. 4B). The slower washout 
of  the  receptor  agonist  18F-FP-MAGBBN  was  also 
likely due to the presence of internalized activity that 
did not readily efflux.  
MicroPET Imaging  
Around  3.7  MBq  (100  μCi)  of  either 
18F-FP-ATBBN,  18F-FP-MATBBN  or  18F-FP-MAGBBN 
was injected intravenously into PC-3 tumor-bearing 
mice  (n  =  3/group  for  each  tracer).  The  lipophilic 
18F-FP-ATBBN  antagonist  showed  almost  no  tumor 
uptake, but rather rapid and prominent activity ac-
cumulation in the liver and intestines (Fig. 5).  
 
 
FIGURE  5.  Decay-corrected  whole-body  coronal  PET 
images of athymic male nude mice bearing PC-3 tumors at 1 
h after injection of 3.7 MBq (100 μCi) of 
18F-FP-ATBBN (A), 
18F-FP-MATBBN  (B), 
18F-FP-AGBBN  (C),  and 
18F-FP-MAGBBN (D). Arrows indicate PC-3 tumors. 
 
18F-FP-AGBBN  agonist  had  some  tumor  accu-
mulation, but also very high liver, bile and intestinal 
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uptake.  After  the  insertion  of 
Gly-Gly-Gly-Arg-Asp-Asn  linker,  both 
18F-FP-MATBBN  (antagonist)  and  18F-FP-MAGBBN 
(agonist)  showed  excellent  images  with  high  tumor 
background contrast. The distinct difference between 
linker-modified tracer and unmodified tracers clearly 
demonstrated  that  the  Gly-Gly-Gly-Arg-Asp-Asn 
linker significantly improved the pharmacokinetics of 
the tracer. The ROI analysis results are summarized in 
Table 1. Both 18F-FP-MAGBBN and 18F-FP-MATBBN 
cleared rapidly from normal nontargeted organs with 
comparably  high  tumor/liver,  tumor/kidney  and 
tumor/muscle  ratios.  However,  18F-FP-MAGBBN 
agonist  showed  much  higher  tumor  uptake  than 
18F-FP-MATBBN antagonist, especially at 30 min p.i. 
(P < 0.01).  
An in vivo blocking study also demonstrated that 
18F-FP-MATBBN  and  18F-FP-MAG  BBN  specifically 
target GRPR. Tumor uptake of 18F-FP-MAGBBN and 
18F-FP-MATBBN  in  the  presence  of  15  mg/kg 
[Lys3]BBN decreased to 0.18 ± 0.01 and 0.08 ± 0.02% 
ID/g at 1 h time point, respectively.  
 
 
Table 1. Comparison of radioactivity accumulation (data obtained from microPET) in selected organs of PC-3 tu-
mor-bearing nude mice after injection of 3.7 MBq (100 μCi) 
18F-FP-MATBBN or 
18F-FP-MAGBBN at different time points (n 
= 3/group, mean ± SD).  
 
 
 
DISCUSSION 
Androgen-independent  prostate  cancer  ex-
presses  GRPR.  Molecular  imaging  probes  based  on 
GRPR  targeting  peptides,  such  as  BBN  derivatives, 
have thus attracted intensive research attention in the 
past  decade.  Although  numerous  radiolabeled  BBN 
tracers have been well documented for prostate can-
cer imaging, very few  18F labeled BBN tracers have 
been reported, and none have translated successfully 
into  the  clinic.  Previously,  we  developed  an 
18F-labeled  BBN  agonist  tracer  for  prostate  cancer 
imaging.  However,  its  image  quality  was  not  very 
good in terms of tumor/background contrast [16]. We 
recently  developed  several  hybrid  peptide  tracers 
based on dual GRPR and integrin receptor targeting 
peptide  heterodimers  [15,  17,  23,  27].  These  hetero-
dimers generally showed improved imaging qualities, 
but their applications were also limited, due to non-
specific targeting and tedious peptide synthesis.  
The  natural  BBN  peptide  is  a  GRPR  agonist, 
originally isolated from frog skin. Logically, most of 
the BBN-peptide-derived molecular probes were de-
veloped as receptor agonists.  Recently a number  of 
comparative  studies  of  radiometal  labeled  BBN  re-
ceptor antagonists and agonists have been reported 
[18, 20-21, 28-31], all of which suggest that the in vivo 
behavior of receptor antagonist is superior to receptor 
18F-FP-MAGBBN 18F-FP-MATBBN
Uptake (%ID/g) 0.5 h 1 h 2 h 0.5 h 1 h 2 h
Tumor  5.54±1.21 2.43±1.02 1.82±0.56 2.81±0.70 1.84±0.30 1.33±0.28
Liver 0.68±0.20 0.12±0.01 0.09±0.01 0.32±0.09 0.13±0.03 0.08±0.01
Kidney 5.17±0.84 0.92±0.60 0.41±0.16 1.68±0.64 0.53±0.07 0.16±0.04
Muscle 0.56±0.12 0.03±0.01 0.01±0.001 0.18±0.05 0.04±0.003 0.02±0.003
T/NT Ratio 0.5 h 1 h 2 h 0.5 h 1 h 2 h
Tumor/Liver 8.27±1.35 19.85±8.21 21.30±6.75 8.93±1.91 15.28±4.13 17.47±4.33
Tumor/Kidney 1.07±0.14 3.19±1.22 4.72±1.20 1.8±0.6 3.5±0.67 8.76±2.92
Tumor/Muscle 9.93±1.99 82.61±9.75 161.78±10.81 15.63±2.2 52.02±5.69 75.36±16.88Theranostics 2011, 1 
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agonist,  despite  the  fact  that  the  antagonist  has  a 
lower receptor-mediated cell uptake and internaliza-
tion  in vitro.  Similar  behavior  was  also  observed  in 
other  G-protein  coupled  receptor  targeting  systems 
such as somatostatin analogs [32]. We initially chose 
to  label  a  known  BBN  receptor  antagonist  ATBBN 
(D-Phe-Gln-Trp-Ala-Val-Gly-His-Leu-NH2CH2CH3) 
[18,  20,  29-31,  33]  with  18F-NFP.  Unexpectedly, 
18F-FP-ATBBN had virtually no PC-3 tumor uptake, 
even though this tumor is known to express high lev-
els  of  GRPR.  The  agonist  18F-FP-AGBBN  had  some 
tumor uptake, but with much higher accumulation in 
the  gallbladder  and  intestines,  similar  to  what  was 
reported  for  the  same  peptide  labeled  with  an 
18F-4-fluorobenzoyl (18F-FB) prosthetic group [16]. The 
poor in vivo fate of the 18F-labeled bombesin agonists 
and  antagonists  called  for  modification  of  the  pep-
tides  to  improve  their  pharmacokinetics  and  tumor 
targeting efficacy. Introduction of PEG, sugar moiety 
and oligo-glycine linkers has been applied to improve 
the  in vivo kinetics of peptides  [2-3]. Representative 
examples include Galacto-RGD [34] and Fluciclatide 
[35], which are currently being tested clinically. Pre-
viously, we have also successfully used PEG and oli-
go-Glycine linkers to improve the pharmacokinetics 
of  RGD  peptides  [36-40].  We  applied  the  similar 
strategy in this study and synthesized a number of 
linker-modified antagonists and agonists. Some of the 
synthesized compounds showed poor imaging qual-
ity  and  thus  were  discarded  after  the  pilot  experi-
ments (see supporting information for the microPET 
imaging results of BBN tracers screened). A new pep-
tide  linker,  Gly-Gly-Gly-Arg-Asp-Asn,  with  6  hy-
drophilic  amino  acids  and  no  net  charge  provided 
best results. This linker has 1) oligo-Glycine to reduce 
steric hindrance encountered during labeling; 2) op-
positely  charged  Arg-Asp  pair  to  increase  hydro-
philicity; and 3) Asn to act as a hydrophilic spacer. 
The  attachment  of  this  linker  onto  the  known  BBN 
derivatives and further radiolabeling led to somewhat 
less receptor binding and cell uptake in vitro. To our 
delight, this linker also led to much increased tumor 
uptake  with  relatively  low  background,  as  clearly 
delineated in the PET images.  
Our  findings  from  this  study  based  on 
18F-labeled  BBN  derivatives  are  different  from  the 
literature reports on  99mTc and  111In-labeled analogs. 
Radiometal (99mTc or  111In) labeled BBN receptor an-
tagonists appear to have higher in vivo tumor uptake 
than their agonist analogs. In the case of  18F-labeled 
BBN agonists and antagonists, we found that the ag-
onists showed greater receptor mediated internaliza-
tion,  significantly  higher  tumor  uptake,  and  pro-
longed retention than did the antagonists. It is also of 
note that 18F-FP-MAGBBN and  18F-FP-MATBBN had 
similar  tumor-to-background  contrast,  but 
18F-FP-MAGBBN had beneficial, higher tumor uptake 
than 18F-FP-MATBBN, especially at early time points. 
With  the  same  tumor/background  contrast,  higher 
tumor uptake means that less radioactivity is needed 
and a patient will be subjected to less  radiation ex-
posure in a clinical setting.  
CONCLUSIONS 
Unlike  the  case  of  radiometal-labeled  chela-
tor-conjugated  bombesin  derivatives,  where  antago-
nists  outperform  agonists,  18F-labeled  agonists  pre-
sented  in  this  work  are  better  than  antagonists  in 
terms  of  receptor-mediated  accumulation  in  tumor 
areas.  By  using  the  new  hydrophilic 
Gly-Gly-Gly-Arg-Asp-Asn linker, we are able to im-
prove the PET image quality of both 18F-labeled ago-
nists and antagonists. The same linker strategy may 
be applied to improve the pharmacokinetics of other 
hydrophobic peptide tracers.  
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